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Autophagy is a complex pathway regulated by numerous
signalling events that recycles macromolecules and may be
perturbed in lysosomal storage disorders (LSDs). During
autophagy, aberrant regulation of the lysosomal Ca2 + efflux
channel TRPML1 [transient receptor potential mucolipin 1
(MCOLN1)], also known as MCOLN1, is solely responsible for
the human LSD mucolipidosis type IV (MLIV); however, the
exact mechanisms involved in the development of the pathology
of this LSD are unknown. In the present study, we provide
evidence that the target of rapamycin (TOR), a nutrient-sensitive
protein kinase that negatively regulates autophagy, directly targets
and inactivates the TRPML1 channel and thereby functional
autophagy, through phosphorylation. Further, mutating these
phosphorylation sites to unphosphorylatable residues proved to
block TOR regulation of the TRPML1 channel. These findings
suggest a mechanism for how TOR activity may regulate the
TRPML1 channel.
Key words: adenosine 5′-phosphate (AMP)-activated protein
kinase, autophagy, lysosomal storage disease, mammalian target
of rapamycin, mucolipidosis type IV, transient receptor potential
channels.
INTRODUCTION
Autophagy is a pathway required for the degradation of cellular
macromolecules [1,2]. During autophagy, double membrane-
bound vesicles (autophagosomes) isolate the cytosolic material
destined for degradation. Subsequently, autophagosomes fuse
with late endosomes to form amphisomes [3,4]. Amphisomes
then coalesce with lysosomes, leading to the formation of
autolysosomes. Because lysosomes carry degradatory enzymes,
the contents of amphisomes are broken down following
autolysosome formation, with the produced metabolites partly
feeding into catabolic pathways to satisfy the cell’s energy
demands [3,4]. Down-regulation of autophagy leads to the
accumulation of misfolded proteins and is speculated to
be involved in chronic or late-evolving diseases, such
as neurodegenerative diseases, including Huntington’s and
Parkinson’s disease [5,6].
In yeast, the cellular energy sensor SNF1 (sucrose non-
fermenting 1), also known as AMPK (AMP-activated protein
kinase), has a role in fully inducing autophagy [7]. However,
mammalian studies demonstrate conflicting roles for AMPK in
autophagy; there have been several studies indicating that AMPK
is an inducer of autophagy [8–10], whereas there is also evidence
that AMPK is an inhibitor of autophagy [11,12]. However,
energetic stress undoubtedly stimulates both AMPK and
autophagy, leading to the degradation of macromolecules
and producing, for example, amino acids. Such substrates can
then ultimately be funnelled into catabolic processes for energy
generation whereas, at the same time, activating feedback loops
that limit the extent of autophagy; for example, amino acids
stimulate the target of rapamycin (TOR), which in turn, negatively
regulates autophagy. TOR is directly activated by an upstream
signalling pathway involving the TSC1–TSC2 (tuberous sclerosis
complex) heterodimer. AMPK directly phosphorylates TSC2,
thereby activating the TSC [13]. There is also evidence suggesting
that AMPK might directly target and inhibit TOR [14] and
AMPK-silencing (by AMPKαRNAI) does result in increased TOR
activity [15].
While investigating the role of AMPK (by silencing its
catalytic subunit, AMPKα, using RNAi) in autophagy and, more
specifically, genes that are involved in autophagic dysfunction
disorders [16–20]), we discovered evidence for a genetic
interaction between AMPK and the lysosomal Ca2 + efflux
channel TRPML1 [transient receptor potential mucolipin 1
(MCOLN1; UniProtKB–Q9GZU1)], also known as MCOLN1.
Interestingly, mutations in MCOLN1 (the name of the TRPML1
gene) are solely responsible for the human lysosomal storage
disorder (LSD) MLIV (mucolipidosis type IV) [21,22].
First described in 1974 [23], MLIV (MIM 252650) is
an autosomal recessive LSD. However, unlike most LSDs,
the abnormal accumulation of macromolecules (sphingolipids,
phospholipids and mucopolysaccharides) is not caused by a
deficiency of lysosomal hydrolases nor related lysosomal proteins
[23–30]. Rather MLIV is thought to result from abnormal sorting
and/or transport of macromolecules along the late endocytic
pathway [25,26]. This late endocytic defect is supported by
experiments in which the uptake of radioactive phospholipids
in cultured cells is increased in the lysosomes of MLIV compared
with normal controls or even cells from individuals with other
LSDs, including mucolipidosis types I–III [26,31]. More studies
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using a mouse model for MLIV have also supported a late
endocytic pathway defect [32–34].
Since TRPML1 pathophysiology results in a very specific
LSD [25,26], we attempted to determine if the dysregulation
of AMPK signalling might play a role in MLIV by leading to
a loss of balance between component transport into lysosomes
and their catabolism. However, a MS-based experiment indicated
that TOR and not AMPK might be directly regulating TRPML1,
even though we initially detected a genetic interaction between
AMPK and MCOLN1. We further characterized the MS-identified
TOR–TRPML1 interaction and provide evidence that TOR
regulates TRPML1 through phosphorylation. The present study
provides additional mechanistic information on the regulation of
autophagy and may provide a framework to better understand
MLIV and other lysosomal and autophagic-related diseases.
EXPERIMENTAL
Materials
All chemicals were of an analytical grade and, unless otherwise
noted, from Sigma-Chemical or Fisher Scientific. [γ -32P]ATP
(specific activity 3000 Ci/mmol) was from PerkinElmer. The
MCOLN1 peptides (RRKCGRDPSEEHSLLVN, RRKCGRD-
PAEEHALLVN, RRKCGRDPAEEHSLLVN, RRKCGRDPSEE-
HALLVN) were synthesized by the UNC High-Throughput
Peptide Synthesis and Array Facility. MHY1485 was synthesized
and the compound identity was verified by LC–MS and NMR,
in-house at North Carolina Central University, as previously
described [35]. The antibodies used were as follows: anti-LC3
[1:1000 (in milk); MBL International], anti-c-Myc [1:40 dilution
for 1 mg/ml lysate for immunoprecipitation (IP); Developmental
Studies Hybridoma Bank, University of Iowa], anti-α-tubulin
(clone B-5-1-2; Sigma–Aldrich) and anti-GFP (A11122 for IP
and A6455 for Western; Molecular Probes). pEGFPC2-MCOLN1
[full-length, wild-type (WT), human and cloned into the EcoRI
and SalI sites] was a generous gift from R. Puertollano (National
Institute of Health, Bethesda, Maryland) and is as previously
described [36]. The myc-TOR, kinase-dead (KD) myc-TOR and
RFP-LC3 plasmids were from Addgene.
Cell culture and transient transfection
Unless otherwise noted, human embryonic kidney (HEK)293T
cells were cultured in complete DMEM (Dulbecco’s modified
Eagle’s medium; Life Technologies) containing 10 % FBS
(Atlanta Biologicals) at 37 ◦C in 5% CO2.
For the transient expression of the myc-TOR protein, the cells
were plated 24 h before the experiments in 15-cm dishes and
then transfected with the plasmid using Lipofectamine 2000
(1 μg of DNA per 2 μl; Invitrogen) following the manufacturer’s
protocols. Note: for some kinase assays, myc-TOR was replaced
with KD myc-TOR. Cells were then harvested, lysed in buffer
A (50 mM Tris/HCl, pH 7.5, protease [Sigma–Aldrich] and
phosphatase [Sigma–Aldrich] inhibitor cocktails and benzonase
nuclease) plus 1.0% Triton X-100 with shaking for 1 h (4 ◦C)
and centrifuged at 16000 g for 10 min (4 ◦C). myc-tagged TOR
was purified from the supernatants via IP using the anti-c-Myc
antibody at a 1:40 dilution for 1 mg/ml lysate and A/G agarose
(Thermo Fisher Scientific) according to the manufacturer’s
instructions and as previously described [37].
Affinity purification and MS
IP–MS of HEK293T cells transiently transfected with human
EGFP–WT–MCOLN1 and treated with 200 nM rapamycin,
200 μM CoCl2 or DMSO (vehicle) were performed in duplicate.
Briefly, protein lysates from the transfected cell lines were lysed
in 100 mM Tris/HCl (pH 8.0), 100 mM NaCl, 2 % Triton X-
100, 1 mM DTT, benzonase nuclease (Thermo Fisher Scientific)
and protease (Sigma–Aldrich) and phosphatase (Sigma–Aldrich)
inhibitor cocktails and subjected to IP with an anti-GFP antibody
(1:500 dilution; Molecular Probes). Following an on-beads
digestion with a FASP Protein Digestion kit (Expedeon) and
sequencing grade-modified trypsin (Promega), phosphopeptide
enrichment was performed from total peptide pools using a Ti-
oxide column (Titansphere Phos-TiO kit, GL Sciences).
The identity of the eluted peptides was determined using an in-
line LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific).
The ion source was operated at 2.0–2.4 kV with the ion transfer
tube temperature set at 275 ◦C. Full MS scan (300–2000 m/z) was
acquired in Orbitrap at 60000 resolution setting; data-dependent
MS2 (tandem mass spectrometry) spectra were acquired in Linear
Trap Quadropole (LTQ) by collision-induced dissociation with the
20 most intense ions. Precursor ions were selected on the basis
of charge states (1, 2 or 3) and intensity thresholds (above 2000)
from the full scan; dynamic exclusion (one repeat during 30 s,
with a 60-s exclusion time window) was also taken into account.
All raw data spectra were searched using SorcererTM-
SEQUEST® (Sage N Research) and the Transproteomic Pipeline.
Data were searched against the human UniProtKB/Swiss-
Prot sequence database (Release 2011_08) supplemented with
common contaminants and further concatenated with its reversed
copy as a decoy (40494 total sequences). Search parameters used
were a precursor mass between 400 and 4500 amu, up to two
missed cleavages, precursor-ion tolerance of 3 amu, accurate mass
binning within PeptideProphet, semi-tryptic digestion, a static
carbamidomethyl cysteine modification, variable methionine
oxidation and variable phosphorylation of serine, threonine and
tyrosine residues. False discovery rates (FDR) were determined
by ProteinProphet and minimum protein probability cut-offs
resulting in a 1% FDR were selected individually for each
experiment.
Site-directed mutagenesis
Site-directed mutagenesis of MCOLN1 was carried out using
the QuikChange II XL Site-Directed Mutagenesis kit (Agilent
Technologies). The primers utilized in the mutagenesis are listed
in the Supplementary Materials and Methods.
Fura-2 Ca2 + imaging
Cells were loaded with 5 μM Fura-2 AM (Life Technologies)
in the culture medium at 37 ◦C for 60 min. The cells were
then washed three times with modified Tyrode’s solution
{150 mm NaCl, 5 mm KCl, 2 mm CaCl2, 1 mm MgCl2, 10 mM
NaHCO3, 10 mm glucose (pH 7.4) [38,39]} and imaged in wide-
field fluorescence mode in a 96-well format with a 20×/0.75
NA Olympus UPlanApo objective lens using a BD Pathway
855 bioimager equipped with 37 ◦C environmental control,
liquid handling and a Nikon A1 confocal microscope (Becton
Dickenson) within 1 h of processing. EGFP was imaged with
a 488/10 nm band-pass excitation filter and a 515 long-pass
emission filter. Ratiometric Fura-2 AM (excitation 340 and
380 nm, emission 435 nm long-pass, ratio = 340/380) imaging
was used to monitor changes in intracellular [Ca2 + ] upon
c© 2015 Authors; published by Portland Press Limited
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Table 1 AMPKα RNAi and AMPKα loss-of-function rescue by MCOLN
Transgene or loss-of-function mutation
AMPKα RNAi rescue
(% expected)
AMPKα loss-of-function allele 1 rescue
(number rescue/total number scored)
AMPKα loss-of-function allele 2 rescue
(number rescue/total number scored)
UAS-S6k (DN) Yes (11) Yes (14/130) Yes (23/122)
UAS-TOR (DN) Yes (13) No (0/68) No (0/42)
UAS-MCOLN (WT) No (0/1312) No (0/1081) No (0/231)
MCOLN1 Yes (16) Yes (8/98) Yes (6/80)
MCOLN2 Yes (14) Yes (6/122) Yes (10/78)
UAS-MCOLN-RNAi Yes (18) Yes (8/130) Yes (10/156)
UAS-AMPKα Yes (100) Yes (22/65) Yes (36/75)
UAS-AMPKγ No No (0/63) No (0/94)
UAS-GFP No No (0/52) No (0/77)
stimulation [38,40]. Laser-based autofocus was performed in
each well prior to the collection of EGFP and Fura-2 images.
ML-SA1 (10 μM, a direct and specific TRPML1 agonist) and
ionomycin (1 μM) were used to induce Ca2 + flux and as a positive
control to induce a maximal response respectively. Time-zero
GFP and Fura-2 ratio images were collected prior to the addition
of compounds/vehicle controls in 10–100 μl well-volumes using
a single-channel automated pipettor followed by the acquisition
of 50 additional Fura-2 ratiometric images at approximately three
images per second. CellProfiler was used for image processing to
tabulate calcium flux traces on a per-cell basis [41].
Kinase assays
Kinase assays were performed according to previously described
methods [42,43]. Briefly, the assays with myc-tagged TOR
were performed at room temperature (RT, 25 ◦C) in 25 μl of
reaction mixture containing 3–12 μg of protein in kinase buffer
(50 mM Hepes, pH 7.0, 75 mM NaCl, 5 mM sodium acetate,
5 mM magnesium chloride, 1 mM DTT, 8% glycerol, 0.1 mM
EDTA, 200 μM AMP and ATP and 2 μCi of [γ -32P]ATP) with or
without the peptide. After a 30-min incubation period, the reaction
mixtures were counted in a scintillation counter.
In vitro phosphorylation
HEK293T cells were transfected with either WT full-length GFP–
MCOLN1 or full-length GFP–MCOLN1S572A/S576A (S572,576/AA)
and myc-TOR (WT), lysed in phosphorylation buffer [50 mM
Tris/HCl (pH 7.4), 100 mM NaCl, 0.5 mM DTT and 10 mM
MgCl2] supplemented with 2% (v/v) Triton X-100 and protease
and serine/threonine phosphatase inhibitors, incubated with or
without 200 nM rapamycin (20 min, RT), then labelled with
2 μCi of [γ -32P]ATP (30 min, RT) and immunoprecipiated using
the anti-GFP antibody and Protein A/G agarose (washed three
times with the phosphorylation buffer). Samples were eluted
using Laemmli buffer, separated by electrophoresis, stained with
Coomassie Brilliant Blue and subjected to autoradiography.
Western blotting
Protein lysates for immunoblotting were prepared by suspending
cell pellets in lysis buffer A plus 1.0 % Triton X-100 with
shaking for 1 h (4 ◦C) and centrifuged at 16000 g for 10 min
(4 ◦C) in 1.5-ml microfuge tubes. Supernatants were collected and
protein concentrations were determined using the Bio-Rad DC
protein assay. Proteins (50 μg) were then boiled in loading buffer
and subjected to SDS/PAGE (Invitrogen), followed by Western
analyses using the primary antibodies. Secondary antibodies
(IRDye infrared antibodies; LI-COR Biosciences) were used at
a dilution of 1:2000. Scanning, analysing and quantification of
blots were performed via the Odyssey Infrared Imaging System
(LI-COR Biosciences). Three or more independent experiments
were performed for all immunoblotting data.
Fly stocks, crosses and rescue experiments
Drosophila melanogaster strains obtained from the Bloomington
Stock Center included the following: w1118, Act-GAL4, Tub-GAL4,
Ubi-GAL4, trpml1 (referred to as MCOLN1 in the present study),
UAS-TRPMLRNAI, UAS-AMPKαRNAI, the SNF1A1 and SNF1A3
mutants, UAS-SNF1A, AMPKK57A, UAS-S6k.KQ, UAS-Tor.TED
and UAS-GFP. UAS-SNF4 and the trpml2 lines (referred to as
MCOLN2) were gifts from D. Kretzschmar (Oregon Health and
Science University) and C. Montell (University of California)
respectively. All flies were maintained at ∼25 ◦C in yeast-
cornmeal vials and all crosses were also performed in cornmeal-
yeasted vials.
For the AMPKα RNAi rescue experiments, males carrying a
transgene or loss-of-function mutation on the second or third
chromosome were mated to virgin females carrying a GAL4
(either Tub-GAL4 or Act-GAL4 respectively). From these crosses,
male progeny carrying the transgene or loss-of-function mutation
and the GAL4 were mated to virgin females carrying UAS-
AMPKαRNAI. The progeny from this second cross were then
scored for rescue, i.e. viable adult flies in spite of AMPKα RNAi
knockdown.
For the AMPKα loss-of-function rescue experiments, males
carrying a transgene or loss-of-function mutation on the second
or third chromosome were mated in parallel to virgin females from
both the SNF1A1 and the SNF1A3 loss-of-function lines. The male
progeny from both of these crosses were scored for rescue, i.e.
viable adult flies in spite of carrying the lethal loss-of-function
mutation/phenotypically, non-bar-eyed males.
Statistical analyses
For all quantified experiments, data are presented as mean
+− S.E.M. ANOVA was used to determine the statistical
significance with significance set at 0.05. For Western blot
quantification, independent experiments (cell preparation, cell
harvest and SDS/PAGE/transfer) were performed three times
(unless otherwise noted). Indirect immunofluorescent detection of
secondary antibody (LI-COR) was scanned and standardized to an
c© 2015 Authors; published by Portland Press Limited
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Figure 1 The phosphorylation state of C-terminal tail serine residues of
TRPML1 (Ser572 and Ser576) regulate autophagy
(A) MS identified unique phosphopeptides in the complete sequence of TRPML1 (UniProtKB –
Q9GZU1) that are absent after rapamycin treatment. The identified phosphopeptide sequences
are in green, phospho-residues are underlined in red and unique peptides absent when
rapamycin was used during cell culture are boxed in magenta. The six predicted transmembrane
domains of TRPML1 are included underlined in blue. (B) HEK293T cells transfected with either
EGFP-tagged WT–MCOLN1; the S51E construct, MCOLN1S51E; or the S572E/S576E construct,
internal standard (tubulin) to calculate and quantify arbitrary units
using the Odyssey Infrared Imaging System with a representative
Western blot shown in each Figure.
RESULTS
MCOLN1 genetically interacts with AMPK
We initially screened through known Drosophila mutations
that produce neurodegenerative phenotypes (including MCOLN)
[18,44] that might interact with AMPK mutants, which also
produce neural degeneration-like phenotypes [16–20]. Although
there are multiple genes that encode TRPML channels in
mammals (MCOLN1, MCOLN2 and MCOLN3, also known as
TRPML1, TRPML2 and TRPML3), there is only a single MCOLN
(TRPML) gene in Drosophila with two previously characterized
gene deletion lines available for study [45]. We therefore utilized
Drosophila genetics to examine the functional consequences of
altered TRPML activity in vivo in a less genetically redundant
system than the TRPML vertebrate genome.
We investigated the relationship between MCOLN and AMPK
gene functions by reducing AMPKα activity through the use
of a transgenic RNAi-based expression system. This previously
characterized AMPK RNAi system phenocopies genetic loss
of AMPKα and only allows Drosophila development to reach
the late pupal/pharate adult stage without producing eclosing
adults [46,47]. Through the use of this transgenic RNAi-based
expression system [46,47], we determined that introducing a
single MCOLN loss-of-function mutation for either MCOLN
allele rescued otherwise lethal AMPKα knockdown animals to
viability/eclosion (Table 1). In addition, heterozygous MCOLN
loss-of-function alleles were able to rescue previously published
[20] null AMPKα lethal loss-of-function alleles to viability
as well, an effect otherwise only observed with dominant-
negative S6 kinase (S6K; in the TOR pathway), which is
known to antagonize AMPK function [48]. In support of these
results, increased TRPML1 expression did not rescue AMPKα
knockdown or loss-of-function animals but actually significantly
antagonized (decreased) the viability of the KD –AMPKα animal
[46] (Supplementary Table S1).
Phosphopeptide purification and MS of TRPML1 identifies novel
phospho-serine sites
Based upon the finding that MCOLN1 and AMPK genetically
interact, we sought to identify possible sites of interaction
(phosphorylation sites) in the TRPML1 protein. Originally, we
hypothesized that AMPK might directly phosphorylate TRPML1
to regulate its autophagic function. Using HEK293T cells,
we transiently transfected human EGFP–WT–MCOLN1, which
leads to its protein localization in late endosomes and lysosomes
(its physiological localization), in addition to the plasma
membrane (Supplementary Figure S1) [49–51]. We subsequently
treated the transfected cells with rapamycin (a TOR antagonist),
CoCl2 (an AMPK activator [47,52]) or DMSO (vehicle) followed
by IP with a GFP antibody to look for phosphorylation changes in
MCOLN1S572E/S576E were treated with or without lysosomal PIs [E-64d + Pepstatin A (10 μg/ml
of each)] for 12 h. The cells were then lysed and immunoblotted with anti-LC3, anti-GFP
[to quantify the GFP–MCOLN1 constructs (∼93 kDa)] and anti-α-tubulin (n=4). (C) The
quantification of the ratio of LC3BII to LC3BI from (B). A ratio of ‘1’ would indicate equal
quantities of LC3BII and LC3BI. (D) The quantification of the relative ratio of GFP to α-tubulin.
c© 2015 Authors; published by Portland Press Limited
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Figure 2 The S572E/S576E TRPML1 phosphomimetic is non-responsive to TRPML1 agonists
Intracellular Ca2 + ([Ca2 + ]i) was investigated using HEK293T cells transfected with either (A) EGFP-tagged WT–MCOLN1; (B) the S572A/S576A construct, MCOLN1S572A/S576A; or (C) the
S572E/S576E construct, MCOLN1S572E/S576E and the TRPML1 agonist ML-SA1. TRPML1 protein expression was monitored by the presence of an EGFP signal measured at an excitation of 488 nm
(F 488). [Ca2 + ]i was monitored with Fura-2 ratios (F 340/F 380). The extracellular Ca2 + ([Ca2 + ]o) was 2 mM and the [ML-SA1] was 10 μM. (D–F) In WT–MCOLN1- and MCOLN1S572A/S576A
-transfected cells (D and E), the Fura-2 ratios increased in response to ML-SA1 and gradually recovered. The change in the Fura-2 ratio for MCOLN1S572E/S576E (F) was negligible.
c© 2015 Authors; published by Portland Press Limited
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Figure 3 The TOR agonist MHY1485 can deactivate the TRPML1 channel through the phosphorylation of Ser572 and Ser576
Intracellular Ca2 + ([Ca2 + ]i) was investigated in HEK293T cells transfected with either (A) EGFP-tagged WT–MCOLN1; (B) the S572A/S576A construct, MCOLN1S572A/S576A; or (C) the S572E/S576E
construct, MCOLN1S572E/S576E. TRPML1 protein expression was monitored by the presence of an EGFP signal measured at an excitation of 488 nm (F 488). [Ca2 + ]i was monitored with Fura-2 ratios
(F 340/F 380). The extracellular Ca2 + ([Ca2 + ]o) was 2 mM and the [MHY1485] was 10 μM. (D–F) In the WT–MCOLN1-transfected cells (D), the Fura-2 ratios decreased in response to MHY1485 and
gradually recovered whereas the Fura-2 ratios of the MCOLN1S572A/S576A -transfected cells (E) were not affected. The change in the Fura-2 ratios for MCOLN1S572E/S576E (F) was negligible; however,
these ratios were well below the MCOLN1S572A/S576A -transfected cells and the recovered WT–MCOLN1-transfected cells.
TRPML1 in response to these stimuli. After peptide digestion,
followed by phosphopeptide enrichment, the peptides were
subjected to MS, whereupon several phosophopeptides
were identified (Figure 1A; Supplementary Table S2).
Interestingly, two peptides (one N-terminal peptide, containing
one predicted phospho-serine residue and one C-terminal peptide,
containing two predicted phospho-serine residues) were absent
from the peptide pool from the cells treated with the TOR
inhibitor rapamycin but present with the other treatments. Based
on these results, we proceeded to further investigate the functional
consequences of mutating these three serine residues to alanine
(non-phosphorylatable) or glutamic acid (a phosphomimetic)
residues individually or, in the case of the C-terminal peptide
containing two serine residues, both residues. In addition, these
findings suggested that TOR, and not AMPK, might be a more
direct regulator or TRPML1.
Phosphorylation of the C-terminal TRPML1 serine residues results
in decreased autophagic flux
To ascertain the extent of functional autophagy as a metric of
TRPML1 activity, we assessed the relative level of microtubule-
associated protein 1A/1B-light chain 3 (LC3). LC3 is one of
c© 2015 Authors; published by Portland Press Limited
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Figure 4 S572A/S576A TRPML1 and the S572E/S576E TRPML1 phosphomimetic are non-responsive to rapamycin
Intracellular Ca2 + ([Ca2 + ]i) was investigated using HEK293T cells transfected with either (A) EGFP-tagged WT–MCOLN1; (B) the S572A/S576A construct, MCOLN1S572A/S576A; or (C) the
S572E/S576E construct, MCOLN1S572E/S576E and the TOR antagonist rapamycin. TRPML1 protein expression was monitored by the presence of an EGFP signal measured at an excitation of 488 nm
(F 488). [Ca2 + ]i was monitored with Fura-2 ratios (F 340/F 380). The extracellular Ca2 + ([Ca2 + ]o) was 2 mM and the [rapamycin] was 10 μM. (D–F) In the WT–MCOLN1-transfected cells (D), the
Fura-2 ratio increased in response to rapamycin and gradually recovered. The changes in the Fura-2 ratios for MCOLN1S572A/S576A and MCOLN1S572E/S576E (E and F) were negligible.
c© 2015 Authors; published by Portland Press Limited
338 R.U. Onyenwoke and others
Figure 5 TRPML1 is phosphorylated by mTOR on Ser572 and Ser576
(A) Kinase assays were performed with purified WT myc-tagged TOR. Synthesized TRPML1
peptides (WT–TRPML1 and TRPML1S572A/S576A ; no phosphorylatable residues) were compared
as TOR substrates. The kinase assays were performed with varying amounts of the substrate
peptides to measure the kinetics (n=3). (B) Kinase assays were performed with either purified
WT–TOR or KD–TOR and the WT–TRPML1 peptide (n=3). The HEK293T cells expressing the
TOR constructs were cultured either in the presence or in the absence of 200 nM rapamycin
for 12 h before purification. (C) In vitro phosphorylation of WT full-length EGFP–TRPML1
(WT) or full-length EGFP–TRPMLS572A/S576A (S572,576/AA). HEK293T cells transfected with
either construct [all cells were additionally transfected with myc-TOR (WT)] were lysed,
incubated with or without 200 nM rapamycin (20 min), labelled with [γ -32P]ATP (30 min)
and immunoprecipiated with an anti-GFP antibody. Samples were separated by electrophoresis,
stained with Coomassie Brilliant Blue (total, lower panel) and subjected to autoradiography (32P,
upper panel). Staining with Coomassie Brilliant Blue showed similar levels of fusion protein in
each lane.
the most selective markers for autophagosomes [53]. Upon
induction of autophagy, LC3-I becomes lipid conjugated with
phosphatidylethanolamine (PE) into LC3-II, which is then
targeted to the membrane of autophagosomes [54,55]. Although
the relative abundance of LC3-II does correlate with the
formation of autophagosomes, it does not indicate whether
these autophagosomes are capable of completing functional
autophagy. Lysosomal protease inhibitors (PIs), for example,
pepstatin A and E-64d, are therefore utilized to allow for the
formation of autolysosomes but to partially prevent the functional
completion of autophagy [56,57]. In this manner, increased
complete autophagy would lead to increased levels of LC3-II in
the presence of the PIs compared with the absence of PIs, whereas
decreased autophagic flux/turnover would result in a similar level
of LC3-II with or without the PIs [56].
Using this assay, the combined S572E/S576E phosphomimetic
mutation of TRPML1 resulted in an inhibition of autophagic
degradation, as evidenced by the increased accumulation of
LC3-II (the membrane-bound form of LC3 that is characteristic
of autophagosomes) that was similar with and without the
PIs; whereas the S51E variant (and S572A/S576A and S51A
variants) of TRPML1 resulted in no significant increase in
LC3-II accumulation (Figures 1B–1D, Supplementary Figure
S2) compared with the WT with or without the PIs. These
results suggested that the C-terminal phospho-serines, and not
the N-terminal phospho-serine, had profound effects on TRPML1
function.
Calcium imaging indicates that phosphorylation of the C-terminal
TRPML1 serine residues results in decreased channel activity
To further ascertain if phosphorylation (at Ser572 and Ser576)
may regulate autophagy through the Ca2 + efflux activity of the
TRPML1 channel, we performed real-time calcium imaging using
the Ca2 + -specific reagent Fura-2 AM [38] in HEK293T cells
transfected with either EGFP–WT–MCOLN1, the S572E/S576E
construct or the S572A/S576A construct. This technique relies
upon the fact that the recombinant overexpressed TRPML1
channel is partially localized to the plasma membrane, allowing
for an easy demonstration of the Ca2 + influx activity of the
channel from the media when activated using an appropriate
agonist [38,51]. The results illustrate that the S572E/S576E
variant was virtually non-responsive to the TRPML1 agonist ML-
SA1 (mucolipin synthetic agonist 1, a known specific agonist
for TRPML1 [39]) in comparison with both the WT and the
S572A/S576A variants (Figure 2, Supplementary Figures S3A,
S3B and S4A), whereas the single variants (S572A, S572E,
etc.) behave similarly to WT (Supplementary Figure S5A and
S5B). Because of the differential response profile with the
S572E/S576E variant [and not S572E or S576E (or S51E) alone],
the S572A/S576A and S572E/S576E variants became our primary
focus.
When MHY1485 (a TOR agonist previously demonstrated to
inhibit autophagy [35]) was utilized in the same assay described
above, the activity of the S572A/S576A construct was unaffected
by the compound even though the WT channel was obviously
inhibited (Figures 3A and 3B; Supplementary Figure S4B).
Because rapamycin treatment led to our initial discovery of these
novel phospho-serine residues, we also assayed the effect of
rapamycin on these channels. Although rapamycin did activate the
WT channel, the response compared with the basal activation was
not statistically significant and again the S572A/S576A construct
was not obviously affected (Figures 4A and 4B; Supplementary
Figure S4C). These results again indicated that TOR may regulate
the TRPML1 channel through the phosphorylation of these two
C-terminal serine residues.
c© 2015 Authors; published by Portland Press Limited


































Figure 6 mTOR inhibits TRPML1 activity during autophagy through phosphorylation
The model in (A) explains how mTOR, AMPK and TRPML1 possibly interact whereas the models presented in (B) and (C) attempt to explain: (1) why loss of AMPK activity alone is lethal in
relation to (2) why loss of both AMPK and TRPML1 activity resulted in the limited viability in the presented Drosophila genetic studies that served as the basis for the present work respectively.
(A) When active (for example, under starvation conditions), AMPK inhibits mTOR (or its downstream effector molecule S6K1) activity, which in turn modulates TRPML1 activity in a feedback loop
(i.e., inactive/less active mTOR leads to increased TRPML1 activity; however, activating TRPML1 increases autophagy, leading to increased amino acid production and activating mTOR; a feedback
loop that regulates/modulates mTOR, AMPK and TRPML1 activity). (B) In the absence of only AMPK activity [due to a condition/state where there is a loss of AMPK activity and not simply due to
nutrient-rich conditions, which can be simply explained by the feedback loop in (A)], negative TOR regulation is significantly lessened (increased TOR activity), probably contributing to the loss of
viability that occurs when AMPK activity is lost, i.e. a complete loss of AMPK activity is known to be developmentally lethal [46,47]. Please note: due to increased mTOR activity, there would also
probably be a significant accumulation of amphisomes and lysosomes, possibly leading to the neurodegeneration phenotype often accompanying a loss of functional AMPK [16–20] (not pictured).
(C) In the absence of both functional AMPK and TRPML1, TOR activity is balanced because (1) the negative regulation of AMPK activity is absent (A), but (2) the positive regulation involving
autophagy, i.e. the production of nutrients, such as amino acids, is also absent, leading to a limited viability in the absence of AMPK activity [58,59] (refer to Table 1 for the viability results) and
explaining the Drosophila genetic study results described in the present work.
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In vitro phosphorylation and kinase assays support a role for the
direct phosphorylation of the TRPML1 channel by the TOR kinase
To determine whether TOR could directly phosphorylate
TRPML1 in vitro, kinase assays were performed to monitor
the incorporation of 32P into modified versions of the TRPML1
C-terminal peptide (refer to the ‘Experimental’ for the exact
sequences of these peptides; Figures 1A, 5A and 5B;
Supplementary Figure S6) [42,43]. In brief, either Ser572 or Ser576
(or both) was replaced with an unphosphorylatable alanine residue
in the C-terminal TRPML1 peptide for the 32P incorporation
assays. The kinase assays revealed that the C-terminal peptide
is indeed a robust TOR substrate (Figures 5A and 5B), whereas
versions of the peptide altered at one or both of the putative serine
residues (S572A/S576A) were relatively poor TOR substrates
(Supplementary Figure S6).
To further illustrate the direct phosphorylation of TRPML1 by
TOR, cells transfected with either the full-length WT channel or
the full-length S572,576/AA mutant were 32P-labelled in either
the presence or the absence of rapamycin (Figure 5C). The
channel was then immunoprecipitated using anti-GFP antibody
and visualized by SDS/PAGE and autoradiography. The WT
channel was significantly more labelled compared with the
S572,576/AA mutant and rapamycin treatment decreased this
labelling, i.e. the result indicates TOR phosphorylates TRPML1
at Ser572 and Ser576.
DISCUSSION
Through the present study, we have provided evidence that the
TRPML1 channel is directly phosphorylated and regulated by
the TOR kinase but that AMPK could still be involved indirectly
through activity on the TOR pathway (Table 1, Figure 6; [58,59]).
Because AMPK also regulates autophagy, it is possible that we
detected the genetic interaction between AMPK and MCOLN1.
The general role of TOR in autophagy is well-documented in the
literature [60]; however, obtaining mechanistic information on
signalling events occurring during autophagy in MLIV is currently
a very active area of study [61] and was further elucidated by the
present study.
When mutated to phosphomimetic residues (serine to glutamic
acid), the C-terminal tail of the channel proved to contain
functionally important serine residues (Ser572 and Ser576). This
finding validates and expands upon previous studies that have
strongly suggested links between TOR and the endocytic system,
e.g. TOR has been localized to endocytic membranes in yeast,
fly and in mammalian cell culture [62–64]. These types of
regulatory findings are neither abundant nor well-characterized in
the literature for any of the TRPML channels beyond large-scale
MS-based phosphorylation analyses of total cell proteins [65,66].
However, Vergarajauregui et al. [51] did attempt to address
whether TRPML1 activity is regulated by phosphorylation.
In one study [51], those authors identified two PKA
(protein kinase A) consensus motifs in the C-terminal tail
of TRPML1, containing Ser557 and Ser559. In addition, they
found that activation of PKA with forskolin promoted TRPML1
phosphorylation whereas the addition of the PKA inhibitor
H-89 abolished TRPML1 phosphorylation and that PKA-
mediated phosphorylation regulated TRPML1 channel activity,
i.e. forskolin treatment decreased TRPML1 channel activity
whereas treatment with H-89 increased TRPML1 channel activity.
Unfortunately, the PKA inhibitor H-89 also inhibits several
other kinases (e.g., S6K1, MSK1 [mitogen- and stress-activated
protein kinase 1], PKA, ROCKII [rho-associated protein kinase
II], PKBα [protein kinase Bα] and MAPKAP-K1b [MAPK
(mitogen-activated protein kinase)-activated protein kinase-1b])
[67–69] through its competitive inhibition of the ATP site [70] and
forskolin resensitizes cell receptors by activating adenylyl cyclase
and increases the intracellular levels of cAMP, thereby activating
cAMP-sensitive pathways, such as PKA [71]. Thus, the lack of
specificity of the PKA activator and inhibitor (forskolin and H-89)
make these results more difficult to interpret. However, it should
be noted that the stimulatory effect of H-89 on TRPML1 function
was not observed when Ser557 and Ser559 were mutated to alanine
residues, indicating that these two residues may be involved in
the negative regulation of TRPML1 [51].
Our results also indicate the negative regulation of TRPML1
due to the phosphorylation of serine residues (however Ser572 and
Ser576 and not Ser557 or Ser559), which also decreases functional
autophagy, illustrated by the lack of LC3-II turnover in the
S572E/S576E mutant (a characteristic of MLIV patients [72],
the MCOLN1− / − mouse model [33,34] and lysosomal storage
diseases in general [73]) and by direct Ca2 + imaging using
a specific TRPML1 agonist, ML-SA1 [39]. Thus, our results
support the typical MLIV pathophysiology and more directly
suggest that the phosphorylation of Ser572 and Ser576 regulate the
TRPML1 channel.
In general, LSDs, a group of over 60 genetic conditions
[74], are due to lysosomal hydrolase deficiencies that lead to
accumulations of their corresponding substrates within lysosomes
[25,26], with mucolipidosis types I – III falling into this particular
and prevalent category of LSDs. This fact makes the occurrence
of MLIV the more interesting because it is due to a loss-of-
function of a presumed Ca2 + channel, which is a mechanism of
autophagy regulation with some support in the literature, i.e. the
exocytosis of lysosomal contents is thought to be regulated by the
release of intralysosomal Ca2 + into the cytosol [75–77]. Thus, our
work expands upon our knowledge of TRP channel regulation
by protein kinases in general, an area of study that does exist
[78–81] but that is lacking for the TRPML channels, and may
aid in the development of treatments for inducing autophagy
activation, a proposed therapeutic strategy for the treatment of
neurodegenerative diseases [82].
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and analysed the data; Maŕıa Dı́az collected the data. Lawrence Forsberg collected and
analysed the data. Michael Major designed the experiments and reviewed the manuscript.
Jay Brenman designed the experiments, wrote the paper and reviewed the manuscript.
ACKNOWLEDGEMENTS
We thank R. Puertollano (NIH, Bethesda, MD) for the pEGFPC2-MCOLN1 construct
and D. Kretzschmar (Oregon Health and Science University, Portland, Oregon) and C.
Montell (University of California-Santa Barbara, CA) for the UAS-SNF4 and trpml2 fly
lines respectively. We are also indebted to Professor Robert Tarran (UNC-Chapel Hill) for
assistance with the confocal imaging experiments. The authors declare that they have no
competing interests.
FUNDING
This work was supported by grants from the state of North Carolina (University Cancer
Research Fund); and the National Institute of Health [grant number 1-DP2-OD007149-01
(to M.B.M) and NS080108 (to J.E.B)].
REFERENCES
1 Klionsky, D.J. (2007) Autophagy: from phenomenology to molecular understanding in
less than a decade. Nat. Rev. Mol. Cell Biol. 8, 931–937 CrossRef PubMed
c© 2015 Authors; published by Portland Press Limited
TOR regulates TRPML1 341
2 Rubinsztein, D.C. (2006) The roles of intracellular protein-degradation pathways in
neurodegeneration. Nature 443, 780–786 CrossRef PubMed
3 Fader, C.M. and Colombo, M.I. (2009) Autophagy and multivesicular bodies: two closely
related partners. Cell Death Differ 16, 70–78 CrossRef PubMed
4 Metcalf, D. and Isaacs, A.M. (2010) The role of ESCRT proteins in fusion events involving
lysosomes, endosomes and autophagosomes. Biochem. Soc. Trans. 38, 1469–1473
CrossRef PubMed
5 Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J., Tanida, I., Ueno, T., Koike, M.,
Uchiyama, Y., Kominami, E. and Tanaka, K. (2006) Loss of autophagy in the central
nervous system causes neurodegeneration in mice. Nature 441, 880–884
CrossRef PubMed
6 Williams, A., Jahreiss, L., Sarkar, S., Saiki, S., Menzies, F.M., Ravikumar, B. and
Rubinsztein, D.C. (2006) Aggregate-prone proteins are cleared from the cytosol by
autophagy: therapeutic implications. Curr. Top. Dev. Biol. 76, 89–101 CrossRef PubMed
7 Wang, Z., Wilson, W.A., Fujino, M.A. and Roach, P.J. (2001) Antagonistic controls of
autophagy and glycogen accumulation by Snf1p, the yeast homolog of AMP-activated
protein kinase, and the cyclin-dependent kinase Pho85p. Mol. Cell. Biol. 21, 5742–5752
CrossRef PubMed
8 Liang, J., Shao, S.H., Xu, Z.X., Hennessy, B., Ding, Z., Larrea, M., Kondo, S., Dumont,
D.J., Gutterman, J.U., Walker, C.L. et al. (2007) The energy sensing LKB1-AMPK pathway
regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or
apoptosis. Nat. Cell Biol. 9, 218–224 CrossRef PubMed
9 Matsui, Y., Takagi, H., Qu, X., Abdellatif, M., Sakoda, H., Asano, T., Levine, B. and
Sadoshima, J. (2007) Distinct roles of autophagy in the heart during ischemia and
reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy.
Circ. Res. 100, 914–922 CrossRef PubMed
10 Meley, D., Bauvy, C., Houben-Weerts, J.H., Dubbelhuis, P.F., Helmond, M.T., Codogno, P.
and Meijer, A.J. (2006) AMP-activated protein kinase and the regulation of autophagic
proteolysis. J. Biol. Chem. 281, 34870–34879 CrossRef PubMed
11 Samari, H.R. and Seglen, P.O. (1998) Inhibition of hepatocytic autophagy by adenosine,
aminoimidazole-4-carboxamide riboside, and N6-mercaptopurine riboside. Evidence for
involvement of amp-activated protein kinase. J. Biol. Chem. 273, 23758–23763
12 Samari, H.R., Moller, M.T., Holden, L., Asmyhr, T. and Seglen, P.O. (2005) Stimulation of
hepatocytic AMP-activated protein kinase by okadaic acid and other
autophagy-suppressive toxins. Biochem. J. 386, 237–244 CrossRef PubMed
13 Inoki, K., Zhu, T. and Guan, K.L. (2003) TSC2 mediates cellular energy response to
control cell growth and survival. Cell 115, 577–590 CrossRef PubMed
14 Cheng, S.W., Fryer, L.G., Carling, D. and Shepherd, P.R. (2004) Thr2446 is a novel
mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status.
J. Biol. Chem. 279, 15719–15722 CrossRef PubMed
15 Bohensky, J., Leshinsky, S., Srinivas, V. and Shapiro, I.M. (2010) Chondrocyte autophagy
is stimulated by HIF-1 dependent AMPK activation and mTOR suppression. Pediatr.
Nephrol. 25, 633–642 CrossRef PubMed
16 Tschape, J.A., Hammerschmied, C., Muhlig-Versen, M., Athenstaedt, K., Daum, G. and
Kretzschmar, D. (2002) The neurodegeneration mutant lochrig interferes with cholesterol
homeostasis and Appl processing. EMBO J 21, 6367–6376 CrossRef PubMed
17 Spasic, M.R., Callaerts, P. and Norga, K.K. (2008) Drosophila alicorn is a neuronal
maintenance factor protecting against activity-induced retinal degeneration. J. Neurosci.
28, 6419–6429 CrossRef PubMed
18 Lessing, D. and Bonini, N.M. (2009) Maintaining the brain: insight into human
neurodegeneration from Drosophila melanogaster mutants. Nat. Rev. Genet. 10, 359–370
CrossRef PubMed
19 Andersen, R.O., Turnbull, D.W., Johnson, E.A. and Doe, C.Q. (2012) Sgt1 acts via an
LKB1/AMPK pathway to establish cortical polarity in larval neuroblasts. Dev. Biol. 363,
258–265 CrossRef PubMed
20 Swick, L.L., Kazgan, N., Onyenwoke, R.U. and Brenman, J.E. (2013) Isolation of
AMP-activated protein kinase (AMPK) alleles required for neuronal maintenance in
Drosophila melanogaster. Biol. Open 2, 1321–1323 CrossRef PubMed
21 Bargal, R., Avidan, N., Ben-Asher, E., Olender, Z., Zeigler, M., Frumkin, A.,
Raas-Rothschild, A., Glusman, G., Lancet, D. and Bach, G. (2000) Identification of the
gene causing mucolipidosis type IV. Nat. Genet. 26, 118–123 CrossRef PubMed
22 Sun, M., Goldin, E., Stahl, S., Falardeau, J.L., Kennedy, J.C., Acierno, Jr, J.S., Bove, C.,
Kaneski, C.R., Nagle, J., Bromley, M.C. et al. (2000) Mucolipidosis type IV is caused by
mutations in a gene encoding a novel transient receptor potential channel. Hum. Mol.
Genet. 9, 2471–2478 CrossRef PubMed
23 Berman, E.R., Livni, N., Shapira, E., Merin, S. and Levij, I.S. (1974) Congenital corneal
clouding with abnormal systemic storage bodies: a new variant of mucolipidosis. J.
Pediatr. 84, 519–526 CrossRef PubMed
24 Merin, S., Livni, N., Berman, E.R. and Yatziv, S. (1975) Mucolipidosis IV: ocular,
systemic, and ultrastructural findings. Invest. Ophthalmol. 14, 437–448 PubMed
25 Chen, C.S., Bach, G. and Pagano, R.E. (1998) Abnormal transport along the lysosomal
pathway in mucolipidosis, type IV disease. Proc. Natl. Acad. Sci. U.S.A. 95, 6373–6378
CrossRef PubMed
26 Bargal, R. and Bach, G. (1997) Mucolipidosis type IV: abnormal transport of lipids to
lysosomes. J. Inherit. Metab. Dis. 20, 625–632 CrossRef PubMed
27 Goebel, H.H., Kohlschutter, A. and Lenard, H.G. (1982) Morphologic and chemical biopsy
findings in mucolipidosis IV. Clin. Neuropathol. 1, 73–82 PubMed
28 Folkerth, R.D., Alroy, J., Lomakina, I., Skutelsky, E., Raghavan, S.S. and Kolodny, E.H.
(1995) Mucolipidosis IV: morphology and histochemistry of an autopsy case. J.
Neuropathol. Exp. Neurol. 54, 154–164 CrossRef PubMed
29 Bargal, R. and Bach, G. (1988) Phospholipids accumulation in mucolipidosis IV cultured
fibroblasts. J. Inherit. Metab. Dis. 11, 144–150 CrossRef PubMed
30 Goldin, E., Blanchette-Mackie, E.J., Dwyer, N.K., Pentchev, P.G. and Brady, R.O. (1995)
Cultured skin fibroblasts derived from patients with mucolipidosis 4 are auto-fluorescent.
Pediatr. Res. 37, 687–692 CrossRef PubMed
31 Bargal, R. and Bach, G. (1989) Phosphatidylcholine storage in mucolipidosis IV. Clin.
Chim. Acta 181, 167–174 CrossRef PubMed
32 Venugopal, B., Browning, M.F., Curcio-Morelli, C., Varro, A., Michaud, N., Nanthakumar,
N., Walkley, S.U., Pickel, J. and Slaugenhaupt, S.A. (2007) Neurologic, gastric, and
opthalmologic pathologies in a murine model of mucolipidosis type IV. Am. J. Hum.
Genet. 81, 1070–1083 CrossRef PubMed
33 Micsenyi, M.C., Dobrenis, K., Stephney, G., Pickel, J., Vanier, M.T., Slaugenhaupt, S.A.
and Walkley, S.U. (2009) Neuropathology of the Mcoln1( − / − ) knockout mouse model
of mucolipidosis type IV. J. Neuropathol. Exp. Neurol. 68, 125–135 CrossRef PubMed
34 Curcio-Morelli, C., Charles, F.A., Micsenyi, M.C., Cao, Y., Venugopal, B., Browning, M.F.,
Dobrenis, K., Cotman, S.L., Walkley, S.U. and Slaugenhaupt, S.A. (2010)
Macroautophagy is defective in mucolipin-1-deficient mouse neurons. Neurobiol. Dis.
40, 370–377 CrossRef PubMed
35 Choi, Y.J., Park, Y.J., Park, J.Y., Jeong, H.O., Kim, D.H., Ha, Y.M., Kim, J.M., Song, Y.M.,
Heo, H.S., Yu, B.P. et al. (2012) Inhibitory effect of mTOR activator MHY1485 on
autophagy: suppression of lysosomal fusion. PLoS One 7, e43418 CrossRef PubMed
36 Vergarajauregui, S. and Puertollano, R. (2006) Two di-leucine motifs regulate trafficking
of mucolipin-1 to lysosomes. Traffic 7, 337–353 CrossRef PubMed
37 Kazgan, N., Williams, T., Forsberg, L.J. and Brenman, J.E. (2010) Identification of a
nuclear export signal in the catalytic subunit of AMP-activated protein kinase. Mol. Biol.
Cell 21, 3433–3442 CrossRef PubMed
38 Dong, X.P., Wang, X., Shen, D., Chen, S., Liu, M., Wang, Y., Mills, E., Cheng, X., Delling,
M. and Xu, H. (2009) Activating mutations of the TRPML1 channel revealed by
proline-scanning mutagenesis. J. Biol. Chem. 284, 32040–32052 CrossRef PubMed
39 Shen, D., Wang, X., Li, X., Zhang, X., Yao, Z., Dibble, S., Dong, X.P., Yu, T., Lieberman,
A.P., Showalter, H.D. and Xu, H. (2012) Lipid storage disorders block lysosomal
trafficking by inhibiting a TRP channel and lysosomal calcium release. Nat. Commun. 3,
731 CrossRef PubMed
40 Barreto-Chang, O.L. and Dolmetsch, R.E. (2009) Calcium imaging of cortical neurons
using Fura-2 AM. J. Vis. Exp. 23, pii: 1067
41 Kamentsky, L., Jones, T.R., Fraser, A., Bray, M.A., Logan, D.J., Madden, K.L., Ljosa, V.,
Rueden, C., Eliceiri, K.W. and Carpenter, A.E. (2011) Improved structure, function and
compatibility for CellProfiler: modular high-throughput image analysis software.
Bioinformatics 27, 1179–1180 CrossRef PubMed
42 Davies, S.P., Carling, D. and Hardie, D.G. (1989) Tissue distribution of the AMP-activated
protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied
using a specific and sensitive peptide assay. Eur. J. Biochem. 186, 123–128
CrossRef PubMed
43 Mahfouz, M.M., Kim, S., Delauney, A.J. and Verma, D.P. (2006) Arabidopsis TARGET OF
RAPAMYCIN interacts with RAPTOR, which regulates the activity of S6 kinase in response
to osmotic stress signals. Plant Cell 18, 477–490 CrossRef PubMed
44 Bonini, N.M. and Fortini, M.E. (2003) Human neurodegenerative disease modeling using
Drosophila. Annu. Rev. Neurosci. 26, 627–656 CrossRef PubMed
45 Venkatachalam, K., Long, A.A., Elsaesser, R., Nikolaeva, D., Broadie, K. and Montell, C.
(2008) Motor deficit in a Drosophila model of mucolipidosis type IV due to defective
clearance of apoptotic cells. Cell 135, 838–851 CrossRef PubMed
46 Johnson, E.C., Kazgan, N., Bretz, C.A., Forsberg, L.J., Hector, C.E., Worthen, R.J.,
Onyenwoke, R. and Brenman, J.E. (2010) Altered metabolism and persistent starvation
behaviors caused by reduced AMPK function in Drosophila. PLoS One 5, pii: e12799
47 Onyenwoke, R.U., Forsberg, L.J., Liu, L., Williams, T., Alzate, O. and Brenman, J.E. (2012)
AMPK directly inhibits NDPK through a phosphoserine switch to maintain cellular
homeostasis. Mol. Biol. Cell 23, 381–389 CrossRef PubMed
48 Montagne, J., Stewart, M.J., Stocker, H., Hafen, E., Kozma, S.C. and Thomas, G. (1999)
Drosophila S6 kinase: a regulator of cell size. Science 285, 2126–2129
CrossRef PubMed
49 Kiselyov, K., Chen, J., Rbaibi, Y., Oberdick, D., Tjon-Kon-Sang, S., Shcheynikov, N.,
Muallem, S. and Soyombo, A. (2005) TRP-ML1 is a lysosomal monovalent cation
channel that undergoes proteolytic cleavage. J. Biol. Chem. 280, 43218–43223
CrossRef PubMed
c© 2015 Authors; published by Portland Press Limited
342 R.U. Onyenwoke and others
50 Soyombo, A.A., Tjon-Kon-Sang, S., Rbaibi, Y., Bashllari, E., Bisceglia, J., Muallem, S.
and Kiselyov, K. (2006) TRP-ML1 regulates lysosomal pH and acidic lysosomal lipid
hydrolytic activity. J. Biol. Chem. 281, 7294–7301 CrossRef PubMed
51 Vergarajauregui, S., Oberdick, R., Kiselyov, K. and Puertollano, R. (2008) Mucolipin 1
channel activity is regulated by protein kinase A-mediated phosphorylation. Biochem. J.
410, 417–425 CrossRef PubMed
52 Lee, M., Hwang, J.T., Lee, H.J., Jung, S.N., Kang, I., Chi, S.G., Kim, S.S. and Ha, J.
(2003) AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1
transcriptional activity and its target gene expression under hypoxic conditions in DU145
cells. J. Biol. Chem. 278, 39653–39661 CrossRef PubMed
53 Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E.,
Ohsumi, Y. and Yoshimori, T. (2000) LC3, a mammalian homologue of yeast Apg8p, is
localized in autophagosome membranes after processing. EMBO J 19, 5720–5728
CrossRef PubMed
54 Tanida, I., Minematsu-Ikeguchi, N., Ueno, T. and Kominami, E. (2005) Lysosomal
turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy.
Autophagy 1, 84–91 CrossRef PubMed
55 Williams, T., Forsberg, L.J., Viollet, B. and Brenman, J.E. (2009) Basal autophagy
induction without AMP-activated protein kinase under low glucose conditions. Autophagy
5, 1155–1165 CrossRef PubMed
56 Mizushima, N. and Yoshimori, T. (2007) How to interpret LC3 immunoblotting.
Autophagy 3, 542–545 CrossRef PubMed
57 Tanida, I., Ueno, T. and Kominami, E. (2008) LC3 and Autophagy. Methods Mol. Biol.
445, 77–88 CrossRef PubMed
58 Wong, C.O., Li, R., Montell, C. and Venkatachalam, K. (2012) Drosophila TRPML is
required for TORC1 activation. Curr. Biol. 22, 1616–1621 CrossRef PubMed
59 Venkatachalam, K., Wong, C.O. and Montell, C. (2013) Feast or famine: role of TRPML in
preventing cellular amino acid starvation. Autophagy 9, 98–100
CrossRef PubMed
60 Alers, S., Loffler, A.S., Wesselborg, S. and Stork, B. (2012) Role of
AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks.
Mol. Cell. Biol. 32, 2–11 CrossRef PubMed
61 Zoncu, R., Efeyan, A. and Sabatini, D.M. (2011) mTOR: from growth signal integration to
cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21–35 CrossRef PubMed
62 Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-Peled, L. and
Sabatini, D.M. (2008) The Rag GTPases bind raptor and mediate amino acid signaling to
mTORC1. Science 320, 1496–1501 CrossRef PubMed
63 Kunz, J., Schneider, U., Howald, I., Schmidt, A. and Hall, M.N. (2000) HEAT repeats
mediate plasma membrane localization of Tor2p in yeast. J. Biol. Chem. 275,
37011–37020 CrossRef PubMed
64 Wedaman, K.P., Reinke, A., Anderson, S., Yates, III, J., McCaffery, J.M. and Powers, T.
(2003) Tor kinases are in distinct membrane-associated protein complexes in
Saccharomyces cerevisiae. Mol. Biol. Cell 14, 1204–1220 CrossRef PubMed
65 Trost, M., English, L., Lemieux, S., Courcelles, M., Desjardins, M. and Thibault, P. (2009)
The phagosomal proteome in interferon-gamma-activated macrophages. Immunity 30,
143–154 CrossRef PubMed
66 Ballif, B.A., Villen, J., Beausoleil, S.A., Schwartz, D. and Gygi, S.P. (2004)
Phosphoproteomic analysis of the developing mouse brain. Mol. Cell. Proteomics 3,
1093–1101 CrossRef PubMed
67 Marunaka, Y. and Niisato, N. (2003) H89, an inhibitor of protein kinase A (PKA),
stimulates Na + transport by translocating an epithelial Na + channel (ENaC) in fetal rat
alveolar type II epithelium. Biochem. Pharmacol. 66, 1083–1089 CrossRef PubMed
68 Lochner, A. and Moolman, J.A. (2006) The many faces of H89: a review. Cardiovasc. Drug
Rev. 24, 261–274 CrossRef PubMed
69 Cho, I.J., Woo, N.R., Shin, I.C. and Kim, S.G. (2009) H89, an inhibitor of PKA and MSK,
inhibits cyclic-AMP response element binding protein-mediated MAPK phosphatase-1
induction by lipopolysaccharide. Inflamm. Res. 58, 863–872 CrossRef PubMed
70 Murray, A.J. (2008) Pharmacological PKA inhibition: all may not be what it seems. Sci.
Signal. 1, re4 CrossRef PubMed
71 Alasbahi, R.H. and Melzig, M.F. (2012) Forskolin and derivatives as tools for studying the
role of cAMP. Die Pharmazie 67, 5–13 PubMed
72 Vergarajauregui, S., Connelly, P.S., Daniels, M.P. and Puertollano, R. (2008) Autophagic
dysfunction in mucolipidosis type IV patients. Hum. Mol. Genet. 17, 2723–2737
CrossRef PubMed
73 Yue, Z., Friedman, L., Komatsu, M. and Tanaka, K. (2009) The cellular pathways of
neuronal autophagy and their implication in neurodegenerative diseases. Biochim.
Biophys. Acta 1793, 1496–1507 CrossRef PubMed
74 Raben, N., Shea, L., Hill, V. and Plotz, P. (2009) Monitoring autophagy in lysosomal
storage disorders. Methods Enzymol 453, 417–449 CrossRef PubMed
75 Luzio, J.P., Bright, N.A. and Pryor, P.R. (2007) The role of calcium and other ions in
sorting and delivery in the late endocytic pathway. Biochem. Soc. Trans. 35, 1088–1091
CrossRef PubMed
76 Pryor, P.R., Mullock, B.M., Bright, N.A., Gray, S.R. and Luzio, J.P. (2000) The role of
intraorganellar Ca(2 + ) in late endosome-lysosome heterotypic fusion and in the
reformation of lysosomes from hybrid organelles. J. Cell Biol. 149, 1053–1062
CrossRef PubMed
77 Reddy, A., Caler, E.V. and Andrews, N.W. (2001) Plasma membrane repair is mediated by
Ca(2 + )-regulated exocytosis of lysosomes. Cell 106, 157–169 CrossRef PubMed
78 Nilius, B., Prenen, J., Tang, J., Wang, C., Owsianik, G., Janssens, A., Voets, T. and Zhu,
M.X. (2005) Regulation of the Ca2 + sensitivity of the nonselective cation channel
TRPM4. J. Biol. Chem. 280, 6423–6433 CrossRef PubMed
79 Jiang, X., Newell, E.W. and Schlichter, L.C. (2003) Regulation of a TRPM7-like current in
rat brain microglia. J. Biol. Chem. 278, 42867–42876 CrossRef PubMed
80 Vazquez, G., Wedel, B.J., Kawasaki, B.T., Bird, G.S. and Putney, Jr, J.W. (2004) Obligatory
role of Src kinase in the signaling mechanism for TRPC3 cation channels. J. Biol. Chem.
279, 40521–40528 CrossRef PubMed
81 Venkatachalam, K., Zheng, F. and Gill, D.L. (2003) Regulation of canonical transient
receptor potential (TRPC) channel function by diacylglycerol and protein kinase C. J. Biol.
Chem. 278, 29031–29040 CrossRef PubMed
82 Garcia-Arencibia, M., Hochfeld, W.E., Toh, P.P. and Rubinsztein, D.C. (2010) Autophagy, a
guardian against neurodegeneration. Semin. Cell Dev. Biol. 21, 691–698
CrossRef PubMed
Received 13 March 2015/17 July 2015; accepted 20 July 2015
Accepted Manuscript online 20 July 2015, doi:10.1042/BJ20150219
c© 2015 Authors; published by Portland Press Limited
